bismuth- containing quadruple and high-dose dual therapy in eradication of Helicobacter pylori infectio

Phase 2

• Conditions: B98.0; Eradication of Helicobacter pylori infection.; ?????????? ?????? ?? ????? ???? ?????? ?? ?? ?? ??? ??? ???? ???? ???? ?? ???

• Registration Number: IRCT20221016056190N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients with chronic gastritis with or without improved PUD caused by Helicobacter pylori
Helicobacter pylori (+) determined by any of the rapid urease test and histopathology, urease breath test, fecal antigen test
Patients who have not received Helicobacter pylori eradication treatment

Exclusion Criteria

Allergy to the drugs used in the study
Use of PPIs, H2 receptor antagonists, antibiotics, bismuth or probiotics in the last 4 weeks before entering the study
Smoking and alcohol abuse
The presence of underlying disease or conditions such as liver disease, cardiovascular disease, lung disease, metabolic disease, or malignant tumor that may affect the study
Pregnant or lactating female patients
Performing esophageal or gastric surgery procedures in the past
Incomplete follow-up or low acceptance capacity of patients in treatment during the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication of Helicobacter pylori infection. Timepoint: 4 weeks after receiving two treatment regimens, the eradication rate of Helicobacter pylori in two groups is compared. Method of measurement: Laboratory method of testing Helicobacter pylori antigen in stool.